William Blair Issues Optimistic Outlook for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at William Blair lifted their Q2 2025 EPS estimates for Zevra Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. William Blair analyst S. Corwin now anticipates that the company will post earnings per share of ($0.09) for the quarter, up from their prior forecast of ($0.17). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics’ Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.29) EPS.

A number of other equities analysts also recently commented on the company. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a report on Wednesday, May 14th. Canaccord Genuity Group boosted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, March 13th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Zevra Therapeutics in a report on Thursday, March 13th. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $22.29.

Zevra Therapeutics Stock Down 3.4%

Shares of ZVRA opened at $8.61 on Monday. The firm has a market cap of $470.79 million, a P/E ratio of -4.37 and a beta of 1.87. The stock has a 50 day simple moving average of $7.57 and a two-hundred day simple moving average of $8.08. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million for the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period last year, the firm posted ($0.40) earnings per share.

Insider Activity

In other Zevra Therapeutics news, Director John B. Bode purchased 10,000 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The shares were acquired at an average price of $7.96 per share, with a total value of $79,600.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at approximately $318,400. This trade represents a 33.33% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Zevra Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Woodline Partners LP raised its holdings in shares of Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock valued at $34,571,000 after buying an additional 476,032 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in Zevra Therapeutics by 462.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after buying an additional 3,001,000 shares during the last quarter. Vanguard Group Inc. lifted its position in Zevra Therapeutics by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock worth $23,554,000 after acquiring an additional 68,151 shares during the period. Altium Capital Management LLC lifted its position in Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock worth $15,429,000 after acquiring an additional 150,000 shares during the period. Finally, AIGH Capital Management LLC raised its stake in shares of Zevra Therapeutics by 82.4% during the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after buying an additional 649,495 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.